Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408364 | 0.88 | MEN1 (0.33) | MEN1KMT2AKDM4EL3MBTL3L3MBTL1 | |
| SCHEMBL20031851 | 0.86 | — | — | |
| SCHEMBL21316726 | 0.85 | MEN1 (0.41) | MEN1KMT2ASMN1; SMN2GAA | |
| SCHEMBL18993481 | 0.79 | MAPK1 (0.32) | — | |
| SCHEMBL21316729 | 0.78 | — | — | |
| SCHEMBL23344688 | 0.76 | — | — | |
| SCHEMBL408977 | 0.76 | HRH3 (0.32) | MEN1KMT2AL3MBTL3L3MBTL1 | |
| SCHEMBL408337 | 0.75 | HRH3 (0.34) | MEN1KMT2AKDM4EL3MBTL3L3MBTL1 | |
| SCHEMBL20032086 | 0.75 | SMPD1 (0.30) | — | |
| SCHEMBL21172177 | 0.74 | MAPK1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139897-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | SAREPTA THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139897-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | MEN1 3261/4885KMT2A 2469/4885KDM4E 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.